COMMENTARY
Is 7.8% Drug Cost Cut Justifiable? Make “Huge Seller” Re-Pricing a Starter to Discuss This
The Central Social Insurance Medical Council (Chuikyo) on December 25 approved a list of plans for the FY2016 drug pricing reform next April. While the pharma industry won the health ministry’s commitment to crafting a long-demanded price maintenance rule for…
To read the full story
COMMENTARY
- Hisamitsu’s MBO: Is Shareholder Accountability Trust-Building or a Shackle?
February 18, 2026
- Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision
February 9, 2026
- Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key
February 5, 2026
- TSE’s Growth Market Reform Puts Pressure on Biotechs
January 27, 2026
- Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026
January 6, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





